Twist Bioscience Corporation updated earnings guidance for the full fiscal year 2024. For the year, Total revenue is expected to be in the range of $288 million to $293 million, growth of 18% to 20%, Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range and Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.37 USD | -1.92% | +2.81% | +14.95% |
05-03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
05-03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.95% | 2.47B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024